《科学》 2026年9月24日 · 中文解读
靶向非典型G蛋白偶联受体信号通路治疗心脏纤维化
Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy · H. Zhang et al.
约 36 分钟Research Summaries在小程序里点播,20 到 60 分钟做好
这篇讲什么
研究人员利用人诱导多能干细胞构建多维药物筛选平台,从约4000种生物活性化合物中筛选出非选择性腺苷受体拮抗剂CGS15943,可抑制心脏成纤维细胞活化且无明显心脏毒性。机制研究表明,三种腺苷受体亚型共同汇聚于Gβγ信号,激活PI3Kγ-AKT和YAP通路驱动纤维化,而CGS15943能阻断这一共享信号轴。该发现为心脏纤维化乃至其他器官纤维化提供了可成药的潜在靶点。
原文开头
INTRODUCTION: Cardiac fibrosis contributes to the progression of diverse heart diseases and independently predicts mortality. Yet no approved therapy directly targets fibrotic remodeling in the heart. Animal models remain essential for validation but cannot support compound screening at scale, and primary human cardiac fibroblasts are available only in limited quantities. These constraints create a need for scalable phenotypic screening platforms built on human cells. RATIONALE: We developed a multidimensional drug discovery platform based on human induced pluripotent stem cells (iPSCs). Reporter iPSC- derived cardiac fibroblasts, in which fluorescence tracks myofibroblast activation, provided the efficacy readout, whereas iPSC- derived cardiomyocytes and endothelial cells served as counterscreens for toxicity. …
摘自《科学》(Science)2026年9月24日,H. Zhang et al.。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。

微信扫码,在小程序里听完整版
不用登录先听一篇 · 或在微信搜索小程序 晨间信号